medigraphic.com
ISSN 0016-3813 (Print)

2014, Number s1

<< Back Next >>

Gac Med Mex 2014; 150 (s1)

Hepatic steatosis (HS) as a factor associated with the presence of metabolic risk in schoolchildren and obese adolescents

Castro MAL, Arriaga CHE, Palacios SGC

Language: Spanish
References: 26
Page: 95-100
PDF size: 216.44 Kb.


ABSTRACT

Introduction: One of the complications associated with obesity is nonalcoholic fatty liver disease (NAFLD), which is defined as an excessive accumulation of fat in hepatocytes, and is characterized by chronic elevation of aminotransferases and ultrasonographic abnormalities (increased echogenicity). In the USA it is now the most common liver disease.Prevalence is around 15-25% in the general population, and this increases to 57.5-75% in obese people. The aim of this study was to evaluate whether hepatic steatosis is a factor associated with the presence of metabolic risk in children and obese adolescents. Materials and methods: A retro- and perspective cross-sectional study in the High Specialty Medical Unit No. 25 of the Mexican Social Security Institute in Monterrey, Nuevo Leon, Mexico, in which the clinical records of patients from 5 to 15 years of age, referred with a diagnosis of obesity, were reviewed in the period of January 1, 2012 to June 30, 2013. Children and adolescent patients diagnosed with obesity were included, but we excluded patients with a history of acute and chronic viral hepatitis and use of antiepileptic and hepatotoxic drugs. For descriptive analysis we used absolute frequencies, percentages, means, and standard deviations. For inferential analysis we used chi-square test, Fisher exact test, and Student t test to establish the association of NAFLD with the studied variables. The odds ratio was measured, considering 95% CI and statistical significance p ‹ 0.05. Results: 160 children and adolescent patients were included with median age 11.23 ± 2.2 years, of which 85 (53.1%) were male and 75 (46.9%) were female. All were obese, with BMI and abdominal circumference greater than the 95th percentile for age. In total, 131 (81.8%) patients had NAFLD and 29 (18.2 %) patients did not. HOMA index was increased by 3.9 ± 2.1 (p ‹ 0.05) in patients in the NAFLD group with a mean of 6.4 ± 4.9 in the group without NAFLD. The cutoff point we found for insulin resistance associated with NAFLD was 9. We found four subjects with high LDL levels of (› 130), and none in the control group. Transaminase levels were significantly higher in the group of patients with NAFLD, ALT greater than 40 U/l in 127 (96.94%) of patients with NAFLD (OR: 63.5; 95% CI: 18.5-217; p ‹ 0.005). LDL-C greater than 130 mg/dl occurred in four (3%) patients with NAFLD, and in none of the patients without NAFLD (p = 0.0001). Acanthosis nigricans was found in 128 (97.7%) patients with NAFLD and in only one (3.4 %) in the group without NAFLD (OR: 1194.7; 95% CI: 119.8-1191.5; p = 0.0001). Conclusion: Obesity and insulin resistance are risk factors for the development of fatty liver in children and adolescents.


REFERENCES

  1. Angulo P. Non alcoholic fatty liver disease. N Engl J Med. 2002;346(16): 1221-31.

  2. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116(6):1413-9.

  3. Calzada-León R. Obesidad en niños y adolescentes. México, D.F.: Editores de Textos Mexicanos; 2003.

  4. Patton HM, Sirlin C, Beheling C, Middleton M, Schwimmer JB, Lavine JE. Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. J Pediatr Gastroenterol Nutr. 2006;43(4):413-27.

  5. Martínez-López E, Domínguez-Rosales JA, Hernández-Nazara ZH, Panduro- Cerda A. Esteatohepatitis no alcohólica. Inv Salud 2005; VII (SUPL 1): 40-47.

  6. Nannipieri M, Gonzalez C, Baldi S, et al. Liver enzimes, the metabolic syndrome, and incident diabetes. Diabetes Care. 2005;28(7):1757-62.

  7. Day CP, James OLW. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998;114(4):842-5.

  8. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006;40(suppl 1):S5-10.

  9. Schwimmer JB, Pardee PE, Lavine JE, Blumkin AK, Cook S. Cardiovascular risk factors and the metabolic syndrome in pediatric non-alcoholic fatty liver disease. Circulation. 2008;118(3):277-83.

  10. Iacobellis G, Moschetta A, Buzzetti R, Ribaudo MC, Baroni MG, Leonetti F. Aminotransferase activity in morbid and complicated obesity: predictive role of fasting insulin. Nutr Metab Cardiovasc Dis. 2007;17(6):442-7.

  11. Loria P, Lonardo A, Bellentani S, Day CP, Marchesini G, Carulli N. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. Nutr Metab Cardiovasc Dis. 2007;17(9):684-98.

  12. Saxena NK, Ikeda K, Jockey DC, Friedman SL, Anania FA. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lead littermates of ob/ob mice. Hepatology. 2002;35(4):762-71.

  13. Kobassi HA, Weigensberg MJ, Ball G, Cruz ML, Shaibi GQ, Goran MI. Relation between acanthosis nigricans and insulin sensitivity in overweight Hispanic children at risk for type 2 diabetes. Diabetes Care. 2004;27(6): 1412-6.

  14. Louthan MV, Theriot JA, Zimmerman E, et al. Decreased prevalence of nonalcoholic liver disease in black obese children. J Pediatr Gastroenterol Nutr. 2005;41(4):426-9.

  15. Kawasaki T, Hashimoto N, Kikuchi T, Takahashi H, Uchiyama M. The relationship between fatty liver and hyperinsulinemia in obese Japanese children. J Pediatr Gastroenterol Nutr. 1997;24(3):317-21.

  16. Arslan N, Buyukgebiz B, Ozturk Y, et al. Fatty liver in obese children: prevalence and correlation with anthropometric measurements and hyperlipidemia. Turk J Pediatr. 2005;47(1):23-7.

  17. Perseghin G, Bonfanti R, Magni S, et al. Insulin resistance and whole body energy homeostasis in obese adolescents with fatty liver disease. Am J Physiol Endocrinol Metab. 2006;291(4):E697-703.

  18. Papandreou D, Rousso I, Mavromichalis I. Update on non-alcoholic fatty liver disease in children. Clin Nutr. 2007;26(4):409-15.

  19. Manco M, Marcellini M, DeVito R, Comparcola D, Sartorelli MR, Nobili V. Metabolic syndrome and liver histology in pediatric nonalcoholic steatohepatitis. Int J Obes (Lond). 2008;32(2):381-7.

  20. Scherlock S, Doodley J. Nutritional and metabolic liver disease. In: Disease of the liver and biliary system. 9.a ed. Londres: Blackwell; 1993. p. 408-33.

  21. Magalotti D, Marchesini G, Ramilli S, et al. Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment. A pilot study. Dig Liver Dis. 2004;36(6):406-11.

  22. Rumack C, Wilson S, Charboneau W. Diagnostic ultrasound, 2a edición. San Luis, Mo, EUA: Ed. Mosby.1998;110-2.

  23. Wilson S, Rosen I, Chin-Sang H, Arenson A. Fatty infiltration of the liver: An imaging challenge. J Can Assoc Radiol. 1982;33(4):227-32.

  24. Fishbein MH, Mogren Ch, Gleason T, Stevens WR. Relationship of hepatic steatosis to adipose tissue distribution in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2006;42(1):83-8.

  25. Sung Ko J, Min Yoon J, Ran Yang H, et al. Clinical and hystological features of nonalcoholic fatty liver disease in children. Dig Dis Sci. 2009;54(10):2225-30.

  26. Hubscher SG. Histological assessment of nonalcoholic fatty liver disease. Histopathology. 2006;49(5):450-65.




2020     |     www.medigraphic.com